HEPION PHARMACEUTICALS, INC. Contingent Consideration Classified as Equity, Fair Value Disclosure
HEPION PHARMACEUTICALS, INC. (HEPA) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $0 as of 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2026-03-12
- 2024-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $0.00.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |